Cytek Biosciences, Inc. CTKB Estimated Litigation Liability, Noncurrent
Estimated Litigation Liability, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent?
- Cytek Biosciences, Inc. (CTKB) reported estimated litigation liability, noncurrent of $6.64M in Q1 2026.
- How has Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent changed year-over-year?
- Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent decreased by 24.7% year-over-year, from $8.82M to $6.64M.
- What is the long-term trend for Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s estimated litigation liability, noncurrent has grown at a -9.1% compound annual growth rate (CAGR), from $10.96M to $6.79M.